Methoxy polyethylene glycol-epoetin beta
Also known as: C.E.R.A., CERA, Continuous Erythropoietin Receptor Activator, Methoxy PEG‑Epoetin beta, Mircera, PEG-epoetin beta
Source Methoxy polyethylene glycol-epoetin beta at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Methoxy polyethylene glycol-epoetin beta (MPG‑EPO), sold as C.E.R.A. or Mircera, is a pegylated erythropoietin analogue approved as a prescription erythropoiesis‑stimulating agent (ESA). It is used to treat anemia associated with chronic kidney disease, both in patients on dialysis and those not yet requiring dialysis. Its long circulating half‑life permits dosing intervals of up to four weeks, offering an alternative to more frequently administered ESAs.
Mechanism of Action
MPG‑EPO is a recombinant erythropoietin molecule linked to a methoxy‑polyethylene‑glycol chain, which prolongs its plasma residence. The molecule binds the erythropoietin receptor on erythroid progenitor cells in the bone marrow, activating JAK2‑STAT5 signalling that drives proliferation, differentiation and survival of red‑cell precursors, ultimately increasing hemoglobin production. The pegylation slows renal clearance, giving a half‑life of roughly 137 hours and enabling extended dosing intervals.
What the Research Shows
Four randomized trials in non‑dialysis chronic kidney disease patients (total 1,155 participants) found MPG‑EPO to be non‑inferior to darbepoetin alfa for raising hemoglobin, with fewer episodes of hemoglobin overshoot and a lower proportion needing red‑cell transfusion, although response was slower. A 2016 review highlighted phase I/II and phase III data confirming feasibility of anemia correction and stable hemoglobin with dosing up to four weeks. Cochrane network meta‑analyses (2023) that pooled >25,000 participants rated the evidence for MPG‑EPO’s effect on transfusion avoidance as very low certainty (OR 0.33, confidence interval crossing 1) and suggested a possible increase in hypertension (OR 1.98, low certainty). Direct comparisons with other ESAs remain sparse and generally inconclusive.
Reported Benefits
Available evidence indicates MPG‑EPO effectively raises and maintains hemoglobin in CKD‑related anemia, achieving target levels comparable to other ESAs. Its long half‑life allows dosing intervals of up to four weeks, potentially reducing injection burden. In head‑to‑head trials, patients receiving MPG‑EPO experienced fewer instances of hemoglobin exceeding the target range and required fewer blood transfusions than those on darbepoetin alfa.
Limitations of the Evidence
The body of high‑quality comparative data is limited; only a handful of head‑to‑head RCTs exist, and most studies are at high or unclear risk of bias. Network meta‑analysis yields very low certainty for transfusion reduction and uncertain effects on mortality or cardiovascular outcomes. Time to hemoglobin response appears longer with MPG‑EPO, and the impact on long‑term safety, especially cardiovascular events, remains inadequately defined.
Safety Considerations
Serious adverse‑event rates were similar between MPG‑EPO and darbepoetin alfa in the small trials cited. However, pooled analyses suggest MPG‑EPO may increase the odds of hypertension compared with placebo (OR ~1.98, low certainty). No distinct safety signals unique to the pegylated formulation have been robustly demonstrated, but overall safety conclusions are limited by the scarcity of large, low‑bias trials.
How It Is Administered
MPG‑EPO is supplied as a sterile solution for subcutaneous or intravenous injection. Because of its extended half‑life, dosing is typically performed every two to four weeks, depending on the clinical protocol and patient response. No specific dosing regimens are provided here, as they are determined by prescribing information and individual patient needs.
Routes of Administration
Goals & Uses
- Treatment of anemia in chronic kidney disease (non-dialysis)Hematology / NephrologyHigh
- Reduction of transfusion requirementsHematologyHigh
- Treatment of anemia in chronic kidney disease (dialysis)Hematology / NephrologyHigh
- Reduce need for blood transfusionsTherapeuticHigh
- Hemoglobin stabilization in CKDHematologyHigh
- Increase hemoglobin levelsTherapeuticHigh
Contraindications
- Active malignancyOncologyModerateUse caution or avoid depending on agent and context
- Pure red cell aplasia (PRCA)HematologicHigh
- Use as a substitute for red blood cell transfusion in patients needing immediate correction of anemiaClinicalHigh
- Known hypersensitivity to the productImmunologicHigh
- Hypersensitivity to methoxy polyethylene glycol-epoetin beta or excipientsImmunologicHigh
- Uncontrolled hypertensionCardiovascularHigh
- Pure red cell aplasia (PRCA) due to prior ESA therapyImmunologicalHigh
Adverse Effects
- Flu‑like symptomsSystemicUncommon
- HypertensionCardiovascularCommonHigh blood pressure
- Injection site reactionsLocalCommon
- Hypersensitivity/anaphylaxisImmunologicalRare
- HeadacheNeurologicCommonPain in the head or upper neck
- Thromboembolic eventsCardiovascularRare
- Injection‑site reactionsLocalCommon
- Pure red cell aplasia (PRCA)Immunological / HematologicalRare
- Thromboembolic events (including stroke, MI, DVT, PE)CardiovascularUncommon
Drug Interactions
- Antihypertensive agentsLow
- CyclosporineModerate
- Iron deficiencyModerate
- Iron supplementsLow
- Concurrent use of other ESAsHigh
Population Constraints
- PregnancyReproductive SafetyRelative
- Patients with active malignancyOncologyRelative
- Pediatric patientsAgeRelative
- Patients with history of cardiovascular disease or strokeCardiovascularRelative
- Elderly patientsAgeRelative
- Pediatric patients <1 yearAgeRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionApprovedApproved: Anemia in chronic kidney disease (dialysis and non‑dialysis)EMA approval 2007.
- United StatesApprovedApproved: Anemia in chronic kidney disease (dialysis and non‑dialysis)Approved by FDA in 2007 as Mircera.
- United KingdomApprovedApproved: Anemia in chronic kidney disease (dialysis and non‑dialysis)MHRA approval aligned with EU.
Approved in the United States (2007), European Union (2007) and United Kingdom (2007) as Mircera for anemia associated with chronic kidney disease, both dialysis‑dependent and non‑dialysis patients.
Evidence & Sources
- Journal ArticleHighAlsalimy N, Awaisu A2014-01-01T00:00:00.000000Z
- Journal ArticleHighPalmer SC, et al.2014-01-01T00:00:00.000000Z
- Journal ArticleHighChung EY, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateSchmid H2016-01-01T00:00:00.000000Z
- Journal ArticleModerateSchmidt RJ2009-01-01T00:00:00.000000Z
Frequently Asked Questions
How does MPG‑EPO differ from other ESAs?
MPG‑EPO is pegylated, giving it a much longer plasma half‑life (≈137 hours) than epoetin alfa or darbepoetin alfa. This permits dosing intervals of up to four weeks, whereas other ESAs usually require weekly or bi‑weekly injections.
Is MPG‑EPO more effective at preventing blood transfusions?
Limited head‑to‑head trials suggest MPG‑EPO may reduce transfusion requirements compared with darbepoetin alfa, but large meta‑analyses rate the evidence as very low certainty, so a definitive benefit cannot be confirmed.
What are the main safety concerns with MPG‑EPO?
Serious adverse events appear comparable to other ESAs, but pooled data indicate a possible increase in hypertension risk. Overall safety data are limited, and long‑term cardiovascular outcomes remain uncertain.
Can MPG‑EPO be given intravenously?
Yes, the product is approved for both subcutaneous and intravenous administration, allowing flexibility based on patient preference or clinical setting.
Why might treatment response be slower with MPG‑EPO?
The extended half‑life leads to a more gradual rise in circulating drug levels, which can lengthen the time needed to achieve target hemoglobin compared with shorter‑acting ESAs.
What is Methoxy polyethylene glycol-epoetin beta?
Methoxy polyethylene glycol-epoetin beta (MPG‑EPO), sold as C.E.R.A. or Mircera, is a pegylated erythropoietin analogue approved as a prescription erythropoiesis‑stimulating agent (ESA). It is used to treat anemia associated with chronic kidney disease, both in patients on dialysis and those not yet requiring dialysis. Its long circulating half‑life permits dosing intervals of up to four weeks, offering an alternative to more frequently administered ESAs.
What is Methoxy polyethylene glycol-epoetin beta used for?
Methoxy polyethylene glycol-epoetin beta is educationally associated with: Treatment of anemia in chronic kidney disease (non-dialysis), Reduction of transfusion requirements, Treatment of anemia in chronic kidney disease (dialysis), Reduce need for blood transfusions, Hemoglobin stabilization in CKD, Increase hemoglobin levels. Educational only — not medical advice.
How is Methoxy polyethylene glycol-epoetin beta administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Methoxy polyethylene glycol-epoetin beta?
Reported adverse effects include: Flu‑like symptoms, Hypertension, Injection site reactions, Hypersensitivity/anaphylaxis, Headache, Thromboembolic events, Injection‑site reactions, Pure red cell aplasia (PRCA), Thromboembolic events (including stroke, MI, DVT, PE). This list is not exhaustive — consult a qualified clinician.
Who should avoid Methoxy polyethylene glycol-epoetin beta?
Recorded contraindications: Active malignancy, Pure red cell aplasia (PRCA), Use as a substitute for red blood cell transfusion in patients needing immediate correction of anemia, Known hypersensitivity to the product, Hypersensitivity to methoxy polyethylene glycol-epoetin beta or excipients, Uncontrolled hypertension, Pure red cell aplasia (PRCA) due to prior ESA therapy. Consult a qualified clinician before use.